Daxor Corporation(DXR)Earnings, Financials & Key Ratios
DXR•NASDAQ
88.6× P/E·Price updated Jun 19, 2026
AboutDaxor Corporation, a medical device company, provides blood volume measurement technology focused on blood volume testing. The company develops and markets BVA-100 Blood Volume Analyzer, a diagnostic blood test to provide safe, accurate, objective quantification of blood volume status and composition compared to patient-specific norms for used in a broad range of medical and surgical conditions. The company was formerly known as Idant Corporation and changed its name to Daxor Corporation in May 1973. Daxor Corporation was incorporated in 1971 and is headquartered in Oak Ridge, Tennessee.Show more
- Revenue$2M-93.8%
- EBITDA$2M+146.0%
- Net Income$536K+91.1%
- EPS (Diluted)0.11+81.5%
- Gross Margin100%+0.5%
- EBITDA Margin96.59%+3893.8%
- Operating Margin29.16%+2959.1%
- Net Margin25.17%+3002.4%
- ROE1.54%+72.4%
DXR Key Insights
Daxor Corporation (DXR) fundamental analysis — strengths, weaknesses & financial health based on data analysis
✓Strengths
- ✓Company is almost debt free
- ✓Trading at only 1.3x book value
✗Weaknesses
- ✗Low quality earnings: Net income not backed by cash flow
- ✗Trading more than 30% below 52-week high
- ✗Low asset turnover indicates capital-intensive operations
* These insights are generated automatically based on available financial data. Please conduct your own research before making investment decisions.
Get notified when DXR posts new earnings or crosses analyst targets
Free. No account needed. Unsubscribe any time.
DXR Price & Volume
Daxor Corporation (DXR) stock price & volume — 10-year historical chart
Loading chart...
DXR Growth Metrics
Daxor Corporation (DXR) revenue, earnings & EPS growth — 3, 5 & 10-year CAGR
Revenue CAGR
10 Years-
5 Years-
3 Years-
TTM86.61%
Profit CAGR
10 Years-
5 Years-
3 Years-51.66%
TTM-58.7%
EPS CAGR
10 Years-
5 Years-
3 Years-54.66%
TTM-18.04%
Return on Capital
10 Years0.29%
5 Years6.85%
3 Years7.36%
Last Year1.74%
DXR Peer Comparison
Daxor Corporation (DXR) competitors in Diagnostics and life science tools — business model, growth, and fundamentals comparison
| Company | Market Cap | Stock Price | P/E Ratio (TTM) | Revenue Growth 1Y | Net Margin | Return on Equity (ROE) | FCF Yield | Debt / Equity |
|---|---|---|---|---|---|---|---|---|
 TFX | 5.62B | 127.00 | -6.27 | -34.61% | -35.89% | -28.27% | 0.87 | |
 HOLX | 16.97B | 76.01 | 30.53 | 1.74% | 13.18% | 11.01% | 0.52 | |
 BAX | 10.27B | 19.89 | -11.37 | 5.72% | -9.7% | -16.5% | 1.64 | |
 BDX | 52.16B | 143.98 | 24.70 | 8.23% | 5.33% | 4.54% | 0.76 | |
 ISRG | 144.48B | 406.78 | 51.69 | 20.51% | 28.15% | 16.89% | 0.02 | |
 NVCR | 1.62B | 14.28 | -11.70 | 8.28% | -25.66% | -50.82% | 0.85 | |
 ABT | 153.68B | 88.38 | 11.57 | 4.59% | 31.88% | 27.26% | 0.32 | |
 MDT | 101.86B | 79.34 | 21.98 | 3.62% | 13% | 9.49% | 0.59 |
Compare DXR vs Peers
Daxor Corporation (DXR) vs competitors — business, growth, and fundamentals comparison against the closest industry rivals.
DXR Income Statement
Daxor Corporation (DXR) annual income statement — 10-year revenue, gross profit & net income history
10Y historyFree accessUpdated daily
| Metric | Dec'16 | Dec'17 | Dec'18 | Dec'19 | Dec'20 | Dec'21 | Dec'22 | Dec'23 | Dec'24 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|
Sales/Revenue | 1.84M | -1.01M | -918.45K | -114.99K | -2.81M | -2.62M | -353.36K | 34.59M | 2.13M | 867.86K |
Revenue Growth % | 124.66% | -155.12% | 9.21% | 87.48% | -2340.47% | 6.81% | 86.49% | 9889.04% | -93.84% | 86.61% |
Cost of Goods Sold | 276.75K | 200.08K | 268.48K | 367.17K | 686.42K | 1M | 1.09M | 177.07K | 0 | 74.64K |
COGS % of Revenue | 15.08% | -19.78% | -29.23% | -319.3% | -24.46% | -38.3% | -307.64% | 0.51% | - | - |
Gross Profit | 1.56M▲ 0% | -1.21M▼ 177.7% | -1.19M▲ 2.0% | -482.16K▲ 59.4% | -3.49M▼ 624.4% | -3.62M▼ 3.5% | -1.44M▲ 60.2% | 34.41M▲ 2489.1% | 2.13M▼ 93.8% | 793.22K▲ 0% |
Gross Margin % | 84.92% | 119.78% | 129.23% | 419.3% | 124.46% | 138.3% | 407.64% | 99.49% | 100% | 91.4% |
Gross Profit Growth % | 120.09% | -177.74% | 2.04% | 59.38% | -624.4% | -3.55% | 60.17% | 2489.09% | -93.81% | - |
Operating Expenses | 367.95K | 203.69K | 299.88K | 380.7K | 734.37K | 1.07M | 1.09M | 939.06K | 1.59M | 2.39M |
OpEx % of Revenue | 20.05% | -20.14% | -32.65% | -331.07% | -26.17% | -41.03% | -307.19% | 2.71% | 74.83% | - |
Selling, General & Admin | 304.87K | 124.6K | 256.76K | 384.18K | 593.52K | 991.31K | 1.09M | 307.36K | 294.19K | 2.33M |
SG&A % of Revenue | 16.61% | -12.32% | -27.96% | -334.1% | -21.15% | -37.91% | -307.19% | 0.89% | 13.81% | - |
Research & Development | 0 | 0 | 0 | 0 | 0 | 0 | -15 | 0 | 0 | 0 |
R&D % of Revenue | - | - | - | - | - | - | 0% | - | - | - |
Other Operating Expenses | 63.08K | 79.09K | 43.12K | -3.48K | 140.85K | 81.68K | 15 | 631.7K | 1.3M | 54.79K |
Operating Income | 1.47M▲ 0% | -1.14M▼ 177.8% | -1.1M▲ 4.0% | -495.7K▲ 54.8% | -1.73M▼ 249.1% | 4.75M▲ 374.4% | 5.25M▲ 10.6% | 329.74K▼ 93.7% | 621.42K▲ 88.5% | 4.7M▲ 0% |
Operating Margin % | 79.95% | 112.92% | 119.45% | 431.07% | 61.67% | -181.56% | -1485.92% | 0.95% | 29.16% | 541.92% |
Operating Income Growth % | 118.62% | -177.85% | 3.96% | 54.82% | -249.14% | 374.36% | 10.58% | -93.72% | 88.46% | - |
EBITDA | 1.24M | -1.57M | -1.27M | -517.14K | -1.72M | 5.49M | 6.11M | 836.56K | 2.06M | 6.84M |
EBITDA Margin % | 67.49% | 155.12% | 138.31% | 449.72% | 61.37% | -210.07% | -1729.22% | 2.42% | 96.59% | 787.97% |
EBITDA Growth % | 116.04% | -226.68% | 19.05% | 59.29% | -233.04% | 418.98% | 11.22% | -86.31% | 146.03% | - |
D&A (Non-Cash Add-back) | -228.75K | -426.82K | -173.2K | -21.44K | 0 | 745.58K | 859.73K | 506.81K | 1.44M | 2.14M |
EBIT | 1.47M | -3.01M | -1.22M | -495.7K | -1.72M | 4.77M | 5.25M | 329.74K | 621.42K | -77.12K |
Net Interest Income | -37.33K | -72.97K | -121.25K | -143.49K | -8.4K | -19.61K | -72.45K | -49.1K | -85.09K | -17.25K |
Interest Income | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 4.64K |
Interest Expense | 37.33K | 72.97K | 121.25K | 143.49K | 8.4K | 19.61K | 72.45K | 49.1K | 85.09K | 12.62K |
Other Income/Expense | 0 | 649.55K | -854.56K | 0 | -8.4K | -19.61K | -72.45K | -49.1K | -85.09K | -2.85M |
Pretax Income | 1.47M▲ 0% | -1.22M▼ 182.8% | -1.22M▼ 0.3% | -495.7K▲ 59.3% | -1.73M▼ 249.1% | 4.75M▲ 374.4% | 5.18M▲ 9.1% | 280.64K▼ 94.6% | 536.33K▲ 91.1% | 1.85M▲ 0% |
Pretax Margin % | 79.95% | 120.14% | 132.65% | 431.07% | 61.67% | -181.56% | -1465.41% | 0.81% | 25.17% | 213.59% |
Income Tax | 11.61K | 24.61K | -332.55K | 0 | -25.28K | 0 | 0 | 0 | 0 | -1.63M |
Effective Tax Rate % | 0.79% | -2.03% | 27.3% | 0% | 1.46% | 0% | 0% | 0% | 0% | -87.98% |
Net Income | 1.46M▲ 0% | -1.24M▼ 185.2% | -885.77K▲ 28.6% | -495.7K▲ 44.0% | -1.71M▼ 244.0% | 4.75M▲ 378.4% | 5.18M▲ 9.1% | 280.64K▼ 94.6% | 536.33K▲ 91.1% | 3.48M▲ 0% |
Net Margin % | 79.32% | 122.57% | 96.44% | 431.07% | 60.77% | -181.56% | -1465.41% | 0.81% | 25.17% | 401.5% |
Net Income Growth % | 115.92% | -185.17% | 28.56% | 44.04% | -244.04% | 378.42% | 9.05% | -94.58% | 91.11% | -58.7% |
Net Income (Continuing) | 1.46M | -1.24M | -885.77K | -495.7K | -1.71M | 4.75M | 5.18M | 280.64K | 536.33K | 3.48M |
Discontinued Operations | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Minority Interest | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
EPS (Diluted) | 0.33▲ 0% | -0.33▼ 200.0% | -0.24▲ 27.3% | -0.12▲ 50.0% | -0.43▼ 258.3% | 1.18▲ 374.4% | 0.60▼ 49.2% | 0.06▼ 89.9% | 0.11▲ 81.5% | 0.70▲ 0% |
EPS Growth % | 113.87% | -200% | 27.27% | 50% | -258.33% | 374.42% | -49.15% | -89.9% | 81.52% | -18.04% |
EPS (Basic) | 0.33 | -0.33 | -0.24 | -0.12 | -0.43 | 1.18 | 0.60 | 0.06 | 0.11 | - |
Diluted Shares Outstanding | 3.83M | 3.77M | 3.74M | 4.19M | 3.94M | 4.04M | 8.58M | 4.63M | 4.84M | 4.98M |
Basic Shares Outstanding | 3.8M | 3.74M | 3.74M | 4.19M | 3.94M | 4.04M | 8.58M | 4.63M | 4.84M | 4.98M |
Dividend Payout Ratio | 7.83% | - | - | - | - | - | - | - | - | - |
DXR Balance Sheet
Daxor Corporation (DXR) balance sheet — assets, liabilities & shareholders' equity
| Metric | Dec'16 | Dec'17 | Dec'18 | Dec'19 | Dec'20 | Dec'21 | Dec'22 | Dec'23 | Dec'24 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|
Total Current Assets | 2.62M | 45.27K | 36.72K | 32.74K | 0 | 764.5K | 37.84K | 25.88K | 18.57K | 0 |
Cash & Short-Term Investments | 2.18M | 1.09M | 0 | 0 | 617.8K | 710.7K | 0 | 0 | 0 | 0 |
Cash Only | 2.18M | 1.09M | 0 | 0 | 617.8K | 710.7K | 0 | 0 | 0 | 0 |
Short-Term Investments | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Accounts Receivable | 45.87K | 45.27K | 33.71K | 32.74K | 29.3K | 30.7K | 17.23K | 14.2K | 9.68K | 1.81K |
Days Sales Outstanding | 9.12 | -16.33 | -13.4 | -103.91 | -3.81 | -4.28 | -17.8 | 0.15 | 1.66 | 4.14 |
Inventory | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Days Inventory Outstanding | - | - | - | - | - | - | - | - | - | - |
Other Current Assets | 2.57M | 1.09M | 357K | 0 | -647.1K | 0 | 0 | 0 | 8.89K | -1.81K |
Total Non-Current Assets | 17.97M | 18.14M | 17.24M | 13.97M | 15.67M | 24.22M | 30.22M | 34.84M | 36.61M | 35.89M |
Property, Plant & Equipment | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Fixed Asset Turnover | - | - | - | - | - | - | - | - | - | - |
Goodwill | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Intangible Assets | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Long-Term Investments | 17.97M | 18.14M | 17.24M | 13.97M | 15.67M | 24.22M | 30.22M | 34.84M | 36.61M | 141.7M |
Other Non-Current Assets | -17.97M | -18.14M | -17.24M | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Total Assets | 20.62M▲ 0% | 19.31M▼ 6.4% | 17.63M▼ 8.7% | 14.2M▼ 19.4% | 16.55M▲ 16.6% | 24.98M▲ 50.9% | 30.26M▲ 21.1% | 34.87M▲ 15.2% | 36.63M▲ 5.1% | 35.9M▲ 0% |
Asset Turnover | 0.09x | -0.05x | -0.05x | -0.01x | -0.17x | -0.10x | -0.01x | 0.99x | 0.06x | 0.02x |
Asset Growth % | -1.29% | -6.37% | -8.72% | -19.43% | 16.56% | 50.92% | 21.13% | 15.23% | 5.06% | 37.95% |
Total Current Liabilities | 7.82K | 75K | 72.5K | 78.75K | 707K | 806.42K | 62.44K | 103.1K | 110.33K | 0 |
Accounts Payable | 7.82K | 75K | 72.5K | 78.75K | 80K | 87.4K | 62.44K | 103.1K | 110.33K | 9.5K |
Days Payables Outstanding | 10.31 | 136.82 | 98.56 | 78.29 | 42.54 | 31.85 | 20.96 | 212.52 | - | 272.52 |
Short-Term Debt | 0 | 0 | 0 | 0 | 627K | 715.8K | 0 | 0 | 0 | 0 |
Deferred Revenue (Current) | -2.18M | -1.02M | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Other Current Liabilities | -7.82K | -75K | -72.5K | 0 | 0 | 3.23K | 0 | 0 | 0 | -9.5K |
Current Ratio | 335.00x | 0.60x | 0.51x | 0.42x | - | 0.95x | 0.61x | 0.25x | 0.17x | - |
Quick Ratio | 335.00x | 0.60x | 0.51x | 0.42x | - | 0.95x | 0.61x | 0.25x | 0.17x | - |
Cash Conversion Cycle | - | - | - | - | - | - | - | - | - | -268.38 |
Total Non-Current Liabilities | 2.8M | 4.33M | 4.45M | 1.34M | 170.69K | 3.02M | 1.23M | 755.66K | 729.97K | 262.93K |
Long-Term Debt | 2.8M | 4.33M | 4.45M | 1.34M | 170.69K | 3.02M | 1.23M | 755.66K | 729.97K | 262.93K |
Capital Lease Obligations | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Deferred Tax Liabilities | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Other Non-Current Liabilities | -2.8M | -4.33M | -4.45M | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Total Liabilities | 5.28M | 5.55M | 4.56M | 1.44M | 877.69K | 3.83M | 1.29M | 858.76K | 840.3K | 272.43K |
Total Debt | 2.8M | 4.33M | 4.45M | 1.34M | 170.69K | 3.02M | 1.23M | 755.66K | 729.97K | 262.93K |
Net Debt | 617.87K | 3.25M | 4.45M | 1.34M | -447.11K | 2.31M | 1.23M | 755.66K | 729.97K | 262.93K |
Debt / Equity | 0.18x | 0.32x | 0.34x | 0.11x | 0.01x | 0.14x | 0.04x | 0.02x | 0.02x | 0.01x |
Debt / EBITDA | 2.26x | - | - | - | - | 0.55x | 0.20x | 0.90x | 0.35x | 0.04x |
Net Debt / EBITDA | 0.50x | - | - | - | - | 0.42x | 0.20x | 0.90x | 0.35x | 0.04x |
Interest Coverage | 39.31x | -15.65x | -9.05x | -3.45x | -205.98x | 242.19x | 72.47x | 6.72x | 7.30x | -6.11x |
Total Equity | 15.34M▲ 0% | 13.76M▼ 10.3% | 13.06M▼ 5.1% | 12.77M▼ 2.3% | 15.68M▲ 22.8% | 21.15M▲ 34.9% | 28.97M▲ 37.0% | 34.01M▲ 17.4% | 35.79M▲ 5.2% | 35.63M▲ 0% |
Equity Growth % | 6.35% | -10.34% | -5.06% | -2.27% | 22.79% | 34.94% | 36.95% | 17.4% | 5.24% | 39.31% |
Book Value per Share | 4.01 | 3.65 | 3.49 | 3.05 | 3.98 | 5.24 | 3.38 | 7.34 | 7.39 | 7.15 |
Total Shareholders' Equity | 15.34M | 13.76M | 13.06M | 12.77M | 15.68M | 21.15M | 28.97M | 34.01M | 35.79M | 35.63M |
Common Stock | 53.17K | 53.17K | 53.17K | 53.17K | 53.17K | 53.17K | 53.17K | 53.17K | 54.09K | 54.59K |
Retained Earnings | 10.38M | 8.48M | 17.06M | 16.57M | 14.86M | 19.61M | 24.79M | 25.09M | 25.63M | 25.26M |
Treasury Stock | -14.72M | -14.97M | -14.86M | -14.86M | -10.62M | -10.62M | -8.77M | -4.83M | -4.5M | -4.5M |
Accumulated OCI | 0 | 0 | 17.06M | 0 | 14.86M | 19.61M | 24.79M | 0 | 0 | 0 |
Minority Interest | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
DXR Cash Flow Statement
Daxor Corporation (DXR) cash flow — operating, investing & free cash flow history
| Metric | Dec'16 | Dec'17 | Dec'18 | Dec'19 | Dec'20 | Dec'21 | Dec'22 | Dec'23 | Dec'24 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|
Cash from Operations | 1.59M | -1.17M | -1.32M | 3.11M | -2.45M | -2.76M | -769.3K | -3.66M | 25.69K | -5.24M |
Operating CF Margin % | 86.78% | 115.91% | 143.24% | -2706.33% | 87.22% | 105.5% | 217.71% | -10.57% | 1.21% | - |
Operating CF Growth % | -91.4% | -173.62% | -12.2% | 336.55% | -178.65% | -12.72% | 72.12% | -375.12% | 100.7% | 161.21% |
Net Income | 1.46M | -1.24M | -885.77K | -495.7K | -1.71M | 4.75M | 5.18M | 280.64K | 536.33K | 3.48M |
Depreciation & Amortization | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Stock-Based Compensation | 10.32K | 13.51K | 83.83K | 199.36K | 377.61K | 729.34K | 786.64K | 631.7K | 0 | 634.62K |
Deferred Taxes | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Other Non-Cash Items | 273.29K | -1.47M | -91.36K | 3.24M | -1.09M | -8.45M | -6.73M | -4.62M | -524.73K | -9.38M |
Working Capital Changes | -136.36K | 1.54M | -338.48K | 165.75K | -30.73K | 216.79K | -9.01K | 52.62K | 14.09K | 28.32K |
Change in Receivables | -401.76K | 389.87K | -345.44K | 3.99K | 3.44K | -1.4K | 13.47K | 3.04K | 4.52K | 8.84K |
Change in Inventory | 0 | 0 | 0 | 0 | 0 | 0 | 22.47K | 0 | 0 | 0 |
Change in Payables | -1.32K | 61.5K | -2.5K | 6.25K | 1.25K | 7.4K | -22.47K | 40.66K | -8.6K | 42K |
Cash from Investing | 0 | 0 | 0 | 5.19M | 367.93K | 74.76K | 2.69M | 2.75M | 1.94M | 6.28M |
Capital Expenditures | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
CapEx % of Revenue | - | - | - | - | - | -0% | -0% | - | 0% | 0% |
Acquisitions | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Investments | - | - | - | - | - | - | - | - | - | - |
Other Investing | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Cash from Financing | -1.59M | 1.17M | 226.39K | -3.11M | 3.07M | 2.85M | 58.6K | 3.66M | -25.69K | 290.4K |
Debt Issued (Net) | -1.04M | 1.53M | 120.06K | -3.11M | -1.17M | 2.85M | -1.79M | -473.51K | -25.69K | 264.28K |
Equity Issued (Net) | -435.32K | -248.2K | 106.33K | 0 | 1000K | 0 | 1000K | 1000K | 0 | -200.63K |
Dividends Paid | -113.99K | -112.1K | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Share Repurchases | -435.32K | -248.2K | -32.22K | 0 | 0 | 0 | 0 | 0 | 0 | -200.63K |
Other Financing | 0 | 0 | 0 | 0 | 201.19K | 0 | 0 | -401.27K | 0 | 226.75K |
Net Change in Cash | 0▲ 0% | -1.09M▲ 0% | -1.09M▲ 0.5% | 5.19M▲ 576.5% | 617.8K▼ 88.1% | 92.9K▼ 85.0% | -710.7K▼ 865.0% | 0▲ 100.0% | 0▲ 0% | 558.77K▲ 0% |
Free Cash Flow | 1.59M▲ 0% | -1.17M▼ 173.6% | -1.32M▼ 12.2% | 3.11M▲ 336.5% | -2.45M▼ 178.7% | -2.76M▼ 12.7% | -769.3K▲ 72.1% | -3.66M▼ 375.1% | 25.69K▲ 100.7% | -4.72M▲ 0% |
FCF Margin % | 86.78% | 115.91% | 143.24% | -2706.33% | 87.22% | 105.5% | 217.71% | -10.57% | 1.21% | -543.7% |
FCF Growth % | -91.4% | -173.62% | -12.2% | 336.55% | -178.65% | -12.72% | 72.12% | -375.12% | 100.7% | 37.25% |
FCF per Share | 0.42 | -0.31 | -0.35 | 0.74 | -0.62 | -0.68 | -0.09 | -0.79 | 0.01 | -0.95 |
FCF Conversion (FCF/Net Income) | 1.09x | 0.95x | 1.49x | -6.28x | 1.44x | -0.58x | -0.15x | -13.02x | 0.05x | -1.35x |
Interest Paid | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 12.62K |
Taxes Paid | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
DXR Key Ratios
Daxor Corporation (DXR) financial ratios — P/E, ROE, debt and 30+ core market and balance-sheet ratios
| Metric | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|
Return on Equity (ROE) | 9.78% | -8.52% | -6.61% | -3.84% | -11.99% | 25.79% | 20.66% | 0.89% | 1.54% | 10.09% |
Return on Invested Capital (ROIC) | 6.93% | -5.2% | -4.77% | -2.35% | -8.85% | 18.41% | 14.68% | 0.76% | 1.31% | 9.97% |
Gross Margin | 84.92% | 119.78% | 129.23% | 419.3% | 124.46% | 138.3% | 407.64% | 99.49% | 100% | 91.4% |
Net Margin | 79.32% | 122.57% | 96.44% | 431.07% | 60.77% | -181.56% | -1465.41% | 0.81% | 25.17% | 401.5% |
Debt / Equity | 0.18x | 0.32x | 0.34x | 0.11x | 0.01x | 0.14x | 0.04x | 0.02x | 0.02x | 0.01x |
Interest Coverage | 39.31x | -15.65x | -9.05x | -3.45x | -205.98x | 242.19x | 72.47x | 6.72x | 7.30x | -6.11x |
FCF Conversion | 1.09x | 0.95x | 1.49x | -6.28x | 1.44x | -0.58x | -0.15x | -13.02x | 0.05x | -1.35x |
Revenue Growth | 124.66% | -155.12% | 9.21% | 87.48% | -2340.47% | 6.81% | 86.49% | 9889.04% | -93.84% | 86.61% |
Related:DXR Dividend History·DXR Revenue History·DXR Price History·DXR P/E History·DXR Financial Ratios·DXR Institutional Holders
DXR Frequently Asked Questions
Daxor Corporation (DXR) stock FAQ — growth, dividends, profitability & financials explained
Growth & Financials
Daxor Corporation (DXR) reported $0.9M in revenue for fiscal year 2024. This represents a 82% decrease from $4.7M in 1995.
Daxor Corporation (DXR) saw revenue decline by 93.8% over the past year.
Yes, Daxor Corporation (DXR) is profitable, generating $3.5M in net income for fiscal year 2024 (25.2% net margin).
Dividend & Returns
Daxor Corporation (DXR) has a return on equity (ROE) of 1.5%. This is below average, suggesting room for improvement.
Daxor Corporation (DXR) had negative free cash flow of $4.7M in fiscal year 2024, likely due to heavy capital investments.